Elanco Expects Revenue 2024 Sales of $4.42B-$4.45B Versus Prior Guidance Of $4.41B-$4.46B, With Adjusted EPS Of $0.89-$0.95 Compared To Previous Guidance Of $0.88-$0.96 Vs. Consensus of $4.429B And $0.92, Respectively
Elanco Expects Revenue 2024 Sales of $4.42B-$4.45B Versus Prior Guidance Of $4.41B-$4.46B, With Adjusted EPS Of $0.89-$0.95 Compared To Previous Guidance Of $0.88-$0.96 Vs. Consensus of $4.429B And $0.92, Respectively
Elanco is tightening financial guidance for the full year 2024, summarized in the following table.
Elanco正在調整2024年全年的財務指導，總結如下表。
|
2024 Full Year (dollars in millions, except per share amounts) |
August Guidance |
November Guidance |
||||||
| Revenue | $4,410 | to | $4,460 | $4,420 | to | $4,450 | ||
| Reported Net Income | $314 | to | $352 | $286 | to | $317 | ||
| Adjusted EBITDA | $900 | to | $940 | $900 | to | $930 | ||
| Reported Earnings per Share | $0.63 | to | $0.71 | $0.58 | to | $0.64 | ||
| Adjusted Earnings per Share | $0.88 | to | $0.96 | $0.89 | to | $0.95 | ||
|
2024年全年 (單位：百萬美元，除每股數據外) |
八月 指導 |
指導 |
||||||
| 營業收入 | $4,410 | to | $4,460 | $4,420 | to | $4,450 | ||
| 報告的淨利潤 | 314美元 | to | $352 | $286 | to | $317 | ||
| Adjusted EBITDA | $900 | to | 940美元 | $900 | to | $930 | ||
| 每股收益報告 | $0.63 | to | 0.71美元 | $0.58 | to | $0.64 | ||
| 每股調整後收益 | $0.88 | to | 0.96美元 | $0.89 | to | 0.95美元 | ||
The tightened 2024 revenue guidance continues to reflect 3% organic constant currency growth inclusive of higher innovation sales contribution, now expected between $420 million to $450 million for the full year, offset by lowered expectations for U.S. Pet Health parasiticides. The impact of foreign exchange rates on revenue is now expected to be a headwind of approximately $25 million. The company is updating its adjusted EBITDA guidance range to reflect expected gross margin headwinds from product mix and manufacturing performance. Offsetting the items impacting adjusted EBITDA, improved expectations for interest expense and tax are reflected in the updated adjusted EPS guidance, with no change to the midpoint of the range.
2024年緊縮的營業收入指引持續反映了3%的有機恒定貨幣增長，包括更高的創新銷售貢獻，全年預期在42000萬美元至45000萬美元之間，爲全年，然而由於對美國寵物健康寄生蟲類藥物的預期降低而偏離。匯率對營業收入的影響預計將成爲約2500萬美元的不利因素。公司正在更新其調整後的調整後息稅折舊攤銷前利潤（EBITDA）指引範圍，以反映預期的產品組合和製造業表現毛利率逆風。抵消影響調整後EBITDA的因素，對利息費用和稅收的預期提高反映在更新的調整後每股收益（EPS）指引中，範圍中點沒有變化。
To support framing of future expectations, the company estimates that in the first half of 2024 revenue of $80 million and adjusted EBITDA of approximately $40 million was directly attributable to the aqua business.
爲支持未來預期框架，公司估計2024年上半年的營業收入爲8000萬美元，調整後的EBITDA約爲4000萬美元，直接歸因於水產品業務。
譯文內容由第三人軟體翻譯。
